• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Bjerkholt Eric

    1/27/25 6:14:09 PM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MGX alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    BJERKHOLT ERIC

    (Last) (First) (Middle)
    C/O METAGENOMI, INC.
    5959 HORTON STREET, 7TH FLOOR

    (Street)
    EMERYVILLE CA 94608

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    01/27/2025
    3. Issuer Name and Ticker or Trading Symbol
    Metagenomi, Inc. [ MGX ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24 - Power of Attorney
    No securities are beneficially owned.
    /s/ Matthew L. Wein, attorney-in-fact 01/27/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MGX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MGX

    DatePrice TargetRatingAnalyst
    5/7/2024$10.00Buy
    H.C. Wainwright
    5/2/2024$16.00 → $6.00Overweight → Neutral
    JP Morgan
    3/5/2024Outperform
    TD Cowen
    3/5/2024$22.00Outperform
    BMO Capital Markets
    3/5/2024$16.00Overweight
    JP Morgan
    3/5/2024$23.00Buy
    Jefferies
    3/5/2024$21.00Buy
    Chardan Capital Markets
    3/5/2024$25.00Overweight
    Wells Fargo
    More analyst ratings

    $MGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Metagenomi Inc.

      SC 13G - Metagenomi, Inc. (0001785279) (Subject)

      11/6/24 4:35:15 PM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Metagenomi Inc.

      SC 13G - Metagenomi, Inc. (0001785279) (Subject)

      5/10/24 6:40:45 PM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGX
    Leadership Updates

    Live Leadership Updates

    See more
    • Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

      EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said

      1/28/25 8:00:00 AM ET
      $CBUS
      $CLLS
      $MGX
      $CLXT
      Agricultural Chemicals
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Metagenomi Announces New Appointment to its Board of Directors

      EMERYVILLE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that Eric Bjerkholt, MBA, CFO of Mirum Pharmaceuticals, Inc., will join Metagenomi's Board of Directors, serving on Metagenomi's Audit and Compensation committees, effective January 27, 2025. "We are excited to welcome Eric to our Board of Directors," said Brian C. Thomas, PhD, CEO and founder of Metagenomi. "His tremendous track record in the pharmaceutical industry as well as his experience in business development and capital formation will be an in

      1/15/25 8:55:00 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGX
    Financials

    Live finance-specific insights

    See more

    $MGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $MGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Metagenomi Announces Preclinical Data for Lead Hemophilia A Program Demonstrating Durable Factor VIII (FVIII) Activity Levels through Twelve Months

      Twelve-month durability data from Metagenomi's ongoing nonhuman primate (NHP) study in hemophilia A remains generally consistent with data previously released at 4.5 months NHPs remain healthy and exhibit normal weight gain; treatment is generally well tolerated Program on track for IND filing in 2026 Company to host conference call with management and Dr. Glenn Pierce, international thought leader in hemophilia A EMERYVILLE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced data from an ongoing preclinical

      9/3/24 4:05:00 PM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems

      EMERYVILLE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced it has regained full global rights to research, develop, manufacture, and commercialize its wholly-owned gene editing technologies, including base editors and RNA-mediated integration systems (RIGS), which were previously subject to exclusive rights granted to Moderna, Inc. Metagenomi and Moderna have mutually agreed to terminate their collaboration on primary hyperoxaluria type 1 (PH1), and rights to develop the PH1

      5/1/24 4:00:00 PM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Metagenomi with a new price target

      H.C. Wainwright initiated coverage of Metagenomi with a rating of Buy and set a new price target of $10.00

      5/7/24 6:26:47 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Metagenomi downgraded by JP Morgan with a new price target

      JP Morgan downgraded Metagenomi from Overweight to Neutral and set a new price target of $6.00 from $16.00 previously

      5/2/24 6:29:35 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TD Cowen initiated coverage on Metagenomi

      TD Cowen initiated coverage of Metagenomi with a rating of Outperform

      3/5/24 7:45:11 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Wapnick Pamela was granted 14,000 shares, increasing direct ownership by 23% to 73,684 units (SEC Form 4)

      4 - Metagenomi, Inc. (0001785279) (Issuer)

      4/3/25 11:58:31 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Thomas Brian C. was granted 32,000 shares, increasing direct ownership by 1% to 2,528,276 units (SEC Form 4)

      4 - Metagenomi, Inc. (0001785279) (Issuer)

      4/3/25 11:58:17 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Irish Jian was granted 23,000 shares, increasing direct ownership by 8% to 321,933 units (SEC Form 4)

      4 - Metagenomi, Inc. (0001785279) (Issuer)

      4/3/25 11:57:48 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGX
    SEC Filings

    See more
    • Metagenomi Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Metagenomi, Inc. (0001785279) (Filer)

      5/14/25 7:15:58 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Metagenomi Inc.

      10-Q - Metagenomi, Inc. (0001785279) (Filer)

      5/13/25 4:40:52 PM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Metagenomi Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Metagenomi, Inc. (0001785279) (Filer)

      5/13/25 4:35:07 PM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025

      - Potential best-in-class extrahepatic in vivo gene editing with all-in-one delivery to the central nervous system (CNS) is a critical milestone for the treatment of neurological disorders - - Advancements demonstrate the ability to specifically integrate correct copies of complete genes, potentially enabling treatment of any disease caused by a loss-of-function mutation - EMERYVILLE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced the presentation of three abstracts at the American Society of Gene & Cell Ther

      5/14/25 6:00:00 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Metagenomi Reports Business Updates and First Quarter 2025 Financial Results

      - Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with durable response through approximately 19 months with an encouraging safety profile - Well capitalized with $226.0 million in cash, cash equivalents and available-for-sale marketable securities as of March 31, 2025 with runway anticipated to support operations into 2027 EMERYVILLE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today reported financial results for the quarter ended March 31, 2025, and provid

      5/13/25 4:30:00 PM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Metagenomi to Present at Upcoming Scientific Meetings

      EMERYVILLE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that the Company will present at two upcoming scientific meetings: an oral presentation at TIDES USA 2025, taking place May 19-22, 2025, at the Manchester Grand Hyatt San Diego, and three poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting, taking place May 13-17, 2025, in New Orleans, LA and virtually. TIDES USA Oral Presentation Details: Title: AI-Guided Metagenomic Discovery of Compact CRISPR Systems for

      5/2/25 7:00:00 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care